Do Obesity Medications Protect the Brain? New Review Finds No Reliable Cognitive Benefits Yet

GLP-1 drugs such as semaglutide and tirzepatide have transformed obesity and type 2 diabetes care, but a new review published in the journal Science finds no reliable proof yet that they protect memory or prevent dementia. The review, led by researchers at the University of Copenhagen’s Novo Nordisk Foundation Center for Basic Metabolic Research with collaborators in Sweden, the United Kingdom, the United States and India, concluded that current obesity medicines alter biological processes tied to cognition, but that no consistent cognitive benefit has been established across clinical settings.

The report, titled “Obesity pharmacotherapies and cognition,” drew on animal studies, observational cohorts, genetic analyses, brain imaging and human clinical trials. It covered GLP-1–based medications and newer therapies that also target the amylin, glucagon and GIP pathways.

The strongest hint of benefit comes from observational data. Large datasets suggest that people with type 2 diabetes taking GLP-1 receptor agonists develop dementia less often — but such studies cannot establish whether the drugs themselves account for the difference, since people taking different diabetes drugs may differ in illness severity and overall health.

Randomized trials in Alzheimer’s disease have not shown clear clinical benefit: in Novo Nordisk’s trials EVOKE and EVOKE+, semaglutide did not slow disease progression in patients with early Alzheimer’s disease, despite changes in several biological markers.

Do Obesity Medications Protect the Brain? New Review Finds No Reliable Cognitive Benefits Yet
Photo: gu.se

Animal studies show the drugs can affect memory and learning, and researchers are testing whether benefits could be indirect. Obesity, type 2 diabetes and blood vessel dysfunction are linked to impaired cognition and higher dementia risk, possibly through insulin resistance and chronic inflammation.

People with obesity or diabetes often have trouble with attention, planning and processing speed — problems tied to metabolic and vascular health that may respond better to treatment than the episodic memory loss typical of Alzheimer’s disease.

It remains unclear whether any cognitive effect comes from direct action on brain cells, better metabolic health, or both. Two ongoing human studies are investigating whether semaglutide affects cognition independently of weight loss.

“We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established. It is also important to identify which patients might benefit,” said Stina Börchers, the review’s first author and a researcher affiliated with the University of Gothenburg and the University of Copenhagen.

“Obesity medicines are becoming increasingly sophisticated, offering new opportunities to understand how metabolic regulation influences brain function. By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function,” said Christoffer Clemmensen, the senior author and a research group leader at the University of Copenhagen.

The researchers are calling for clinical trials that track memory and other cognitive abilities from the start of treatment, and they stress the need to monitor older and frail patients, in whom rapid weight loss and muscle loss could reduce any potential benefit. Whether these drugs can genuinely protect the aging brain, and in whom, has not yet been answered.

Photo of author

Health Desk

Health Desk at Archyde.

University of Utah Researchers Identify BLST Protein as Key to Protecting Spinal Discs from Aging

Background Actor Alexander Haskin Identified as Man Who Drowned at Santa Monica Pier